RBC Capital Reiterates Outperform on Edwards Lifesciences, Maintains $96 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Shagun Singh has reiterated an Outperform rating on Edwards Lifesciences (NYSE:EW) and maintained a $96 price target.
August 01, 2023 | 2:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edwards Lifesciences (NYSE:EW) has been reiterated with an Outperform rating by RBC Capital, with a maintained price target of $96.
The reiteration of an Outperform rating by RBC Capital indicates a positive outlook for Edwards Lifesciences. The maintained price target of $96 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100